PTJ
CBIO

Paul Tudor Jones’s Crescent Biopharma CBIO Stock Holding History

Paul Tudor Jones’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-165
Closed -$51K – 1429
2020
Q3 		$51K Sell
165
-272
-62% -$104K ﹤0.01% 1214
2020
Q2 		$164K Sell
437
-90
-17% -$25.5K 0.01% 1049
2020
Q1 		$120K Buy
527
+110
+26% +$42K 0.01% 907
2019
Q4 		$220K Buy
417
+82
+24% +$44.4K 0.01% 962
2019
Q3 		$144K Buy
+335
New +$215K ﹤0.01% 980
2016
Q3 		– Sell
-550
Closed -$400K – 1533
2016
Q2 		$400K Buy
+550
New +$379K 0.01% 993

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Paul Tudor Jones's CBIO Position: Q4 2020 in Review

Paul Tudor Jones sold out of Crescent Biopharma (CBIO) in Q4 2020, closing a stake of 165 shares — an estimated $51K sold.

Paul Tudor Jones first reported a position in CBIO in Q2 2016 and held it in 6 quarters. The position peaked at $400K in Q2 2016. 89 funds tracked by Wall St. Rank hold CBIO as of Q4 2020.

  • Paul Tudor Jones reported no remaining Crescent Biopharma position as of Q4 2020 after selling out during the quarter.
  • Paul Tudor Jones sold 165 Crescent Biopharma shares in Q4 2020, an estimated $51K.
  • Paul Tudor Jones first reported a position in Crescent Biopharma in Q2 2016 and held it in 6 quarters.
  • Paul Tudor Jones's Crescent Biopharma position peaked at $400K in Q2 2016.
  • 89 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2020.

Based on Tudor Investment Corp's 13F filing for Q4 2020, filed 16 Feb 2021.